<DOC>
	<DOCNO>NCT00858871</DOCNO>
	<brief_summary>The purpose study compare overall survival brivanib versus sorafenib subject advance HCC receive prior systemic therapy .</brief_summary>
	<brief_title>First Line Hepato Cellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Histologic cytologic confirm diagnosis HCC . Advanced HCC : disease eligible surgical and/or locoregional therapy OR progressive disease surgical and/or locoregional therapy ChildPugh Class A ECOG performance status 01 Adequate hematologic , hepatic , renal function Prior use systemic anticancer chemotherapy , immunotherapy molecular target agent HCC History active cardiac disease Thrombotic embolic event within past 6 month ( except HCC tumor thrombus ) Any hemorrhage/bleeding event &gt; = CTCAE Grade 3 within 8 week except esophageal gastric varix Inability swallow tablet untreated malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>